New York, NY (March 4th, 2019) – LB Pharmaceuticals, Inc., (“LB”, or the “Company”) a biotechnology company focused on developing and commercializing novel and improved  versions of successful CNS treatments, today announced the closing of an $8.4 million Series A Preferred Stock financing through a private placement to existing and new shareholders.Existing shareholders included Rivopharm […]

JUPITER, Fla., Aug. 22, 2018 /PRNewswire/ — Jupiter Orphan Therapeutics, Inc. (“JOT”), Jupiter, FL, today announced that it has received new data regarding an increase in mitochondrial biogenesis in liver and brain from a recently performed study in a frequently studied Alzheimer’s disease animal model, the triple transgenic (APPsw / PS1M146V / TauP301L) mouse. Daily oral treatment, 50mg/kg, of

June 13, 2018Fort Worth, Texas – Nacuity Pharmaceuticals, Inc. (Nacuity) announces that it has entered into an agreement with Johns Hopkins University (JHU) providing Nacuity with an exclusive worldwide license to the intellectual property (IP) underlying certain U.S. and foreign patent applications that Nacuity has filed in collaboration with the Johns Hopkins Wilmer Eye Institute.

Proceeds will support the development of new generations of cannabinoid-1 (CB1) receptor inverse agonists for the treatment of several metabolic diseases including Prader-Willi Syndrome (PWS) and type 1 diabetes (T1D). MONTREAL (CANADA) – 25 July 2018 – Today Inversago Pharma Inc. (“Inversago”) announced that it has secured a $7 million series A financing to pursue

JUPITER, Fla., Aug. 22, 2017 /PRNewswire/ — Jupiter Orphan Therapeutics, Inc. (“JOT”), Jupiter, FL, today announced that it has received notification from the US Food and Drug Administration (FDA) that its Orphan Drug Designation request for trans-Resveratrol has been granted. “Orphan Drug Designation serves as an important milestone for JOT as it positions our JOTROL™